Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
Marthe Kirkesaether BrunGuro Løvik GollKristin Kaasen JørgensenJoseph SextonJohanna Elin GehinØystein SandangerInge Christoffer OlsenRolf Anton KlaasenDavid John WarrenCato MørkTore K KvienJørgen JahnsenNils BolstadEspen A HaavardsholmSilje Watterdal SyversenPublished in: Journal of internal medicine (2022)
Several risk factors for ADAb formation during early-phase infliximab treatment were identified. This knowledge provides a basis for treatment strategies to mitigate the formation of ADAb and identify patients in whom these measures are of particular importance.